4. Study characteristics of the agreement analyses studies.
| Study | MRI | Index biopsy | Target conditions | ||||||
| Study | Consecutive enrolment (study designa) | N of participants | Index tests | MRI‐scale; threshold | MRI‐TBx | SBx | MRI‐TBx & SBx | ISUP grade (G) | |
| Technique | Median N cores (range) | Independence | Route | ||||||
| Alberts 2017 | Yes (prospective) | Bx‐naïve: 74 Prior‐negative Bx: 84 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Software | 12 (12‐12b) |
Yes | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Boesen 2017a | Unclear (prospective) | 206 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Software | 10 (10‐10) |
Yes | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Boesen 2018 | Yes (prospective) | 1020 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Software | 10c | Yes | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Castellucci 2017 | Yes (prospective) | 168 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Cognitive | (8‐19) | Unclear | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Chang 2017 | Yes (retrospective) | 65 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Cognitive | 18 (16.2‐19.8b) | No | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Chen 2015 | Yes (prospective) | 420 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Cognitive | 12d | Yes | Transperineal | G ≥ 2 |
| Cool 2016 | Unclear (prospective) | Bx‐naïve: 50 Prior‐negative Bx: 50 | MRI‐pathway vs. SBx | Other | Software | 12‐14e | Unclear | Transrectal | G = 1 G ≥ 2 |
| Costa 2013 | No (retrospective) | 38 | MRI‐pathway vs. SBx | 1‐5; ≥4 | Cognitive | NR | No | Transrectal | G ≥ 2 G ≥ 3 |
| Delongchamps 2013 | Yes (prospective) | 391 | MRI‐pathway vs. SBx | TZ: 0‐4; ≥2 PZ: 0‐10; ≥6 | Software Cognitive |
12 (10‐12) |
Unclear | Transrectal | G ≥ 2 |
| Filson 2016 | Yes (prospective) | Bx‐naïve: 329 Prior‐negative Bx: 324 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Software | 12 | Unclear | Transrectal | G ≥ 2 G ≥ 3 |
| Garcia Bennett 2017 | Unclear (prospective) | 60 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Cognitive | 12 | Yes | Transperineal | G = 1 G ≥ 2 G ≥ 3 |
| Grönberg 2018 | Yes (prospective) | Bx‐naïve: 387 Prior‐negative Bx: 145 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Software | 11 (10‐12) |
No | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Jambor 2015 | Unclear (unclear) | 53 | MRI‐pathway vs. SBx | 1‐5; ≥4 | Cognitive | 12 | Yes | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Jambor 2017 | Unclear (prospective) | Bx‐naïve: 134 Prior‐negative Bx: 27 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Cognitive | 12c | No | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Kim 2017 | Unclear (retrospective) | Bx‐naïve: 183 Prior‐negative Bx: 154 | MRI‐pathway vs. SBx | 1‐5; ≥4 | Software Cognitive | 14c | No | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Lee 2016 | Unclear (retrospective) | 76 | MRI‐pathway vs. SBx | 1‐4; ≥2 | Cognitive | 12 (12‐12) |
No | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Lee 2017 | Unclear (retrospective) | 123 | MRI‐pathway vs. SBx | 1‐4; ≥2 | Cognitive | 12 | No | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Okcelik 2016 | Unclear (prospective) | 52 | MRI‐pathway vs. SBx | 0‐1: ≥1 | Cognitive | NR | Unclear | Transrectal | G = 1 G ≥ 2 |
| Panebianco 2015 | Yes (prospective) | Bx‐naïve: 570 Prior‐negative Bx: 355 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Cognitive | 10, 14 or 45f | Unclear | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Peltier 2015 | Yes (prospective) | 110 | MRI‐pathway vs. SBx | 1‐4; ≥2 | Software | 15 (12‐18) | No | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Pokorny 2014 | Yes (prospective) | 223 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | In‐bore | 12 | Unclear | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Rouvière 2019a | Yes (prospective) | 251 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | Software Cognitive |
12.2c | Yes | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Say 2016 | Yes (retrospective) | 143 | MRI‐pathway vs. SBx | 1‐4; ≥2 | Software | 12c | Unclear | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Tonttilla 2016 | Yes (prospective) | 53 | MRI‐pathway vs. SBx | 1‐4; ≥2 | Cognitive | 12 (12‐14) |
Yes | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Van der Leest 2018 | Yes (prospective) | 626 | MRI‐pathway vs. SBx | 1‐5; ≥ 3 | In‐bore | 12c | Yes | Transrectal | G = 1 G ≥ 2 G ≥ 3 |
| Bx: biopsy; ISUP G : International Society of Urological Pathology grade; MRI: magnetic resonance imaging; MRI‐pathway: magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; MRI‐TBx: magnetic resonance imaging‐targeted biopsy; N: number; NA: not applicable; PI‐RADS v1, v2: Prostate Imaging Reporting Data System version 1 or 2; PZ: peripheral zone; SBx: systematic biopsy; TSB: transperineal saturation biopsy; TTMB: transperineal template mapping biopsy; TZ: transition zone | |||||||||
aIncluded participants were part of the same study cohort (no randomised populations were included). bInterquartile range (as opposed to range). cMean value (as opposed to median value). d10 cores in peripheral zone, two cores in transition zone. e2 additional cores in transitional zone in prior‐negative Bx men. f10 and 14 in Bx‐naïve men with positive and negative MRI, respectively; 10 and 45 in prior‐negative Bx men with a positive and negative MRI, respectively.